$1.50
2.17% day before yesterday
Nasdaq, Dec 27, 09:41 pm CET
ISIN
US0547544033
Symbol
AYTU

Aytu BioScience Inc Stock price

$1.52
-0.10 6.17% 1M
-1.34 46.85% 6M
-1.32 46.48% YTD
-1.46 48.99% 1Y
-28.08 94.86% 3Y
-195.42 99.23% 5Y
-2,220,536.08 100.00% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.01 0.87%
ISIN
US0547544033
Symbol
AYTU

Key metrics

Market capitalization $9.35m
Enterprise Value $7.43m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 0.10
P/S ratio (TTM) P/S ratio 0.12
P/B ratio (TTM) P/B ratio 0.31
Revenue growth (TTM) Revenue growth -25.89%
Revenue (TTM) Revenue $75.48m
EBIT (operating result TTM) EBIT $-1.53m
Free Cash Flow (TTM) Free Cash Flow $-2.50m
Cash position $20.11m
EPS (TTM) EPS $-1.22
P/E forward 2.53
P/S forward 0.13
EV/Sales forward 0.11
Short interest 3.92%
Show more

Is Aytu BioScience Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Aytu BioScience Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Aytu BioScience Inc:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Aytu BioScience Inc:

Buy
100%

Financial data from Aytu BioScience Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
75 75
26% 26%
100%
- Direct Costs 29 29
34% 34%
38%
47 47
20% 20%
62%
- Selling and Administrative Expenses 38 38
34% 34%
51%
- Research and Development Expense 2.61 2.61
28% 28%
3%
6.17 6.17
290% 290%
8%
- Depreciation and Amortization 7.70 7.70
14% 14%
10%
EBIT (Operating Income) EBIT -1.53 -1.53
87% 87%
-2%
Net Profit -6.25 -6.25
74% 74%
-8%

In millions USD.

Don't miss a Thing! We will send you all news about Aytu BioScience Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Aytu BioScience Inc Stock News

Neutral
Accesswire
25 days ago
DENVER, CO / ACCESSWIRE / December 3, 2024 / SUMMARY NOTICE OF PENDENCY OF DERIVATIVE ACTION, AGREEMENT OF SETTLEMENT AND RELEASE WITH RESPECT TO CERTAIN PARTIES, AND SETTLEMENT HEARING IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE LITIGATION STYLED WITMER V. ARMISTICE CAPITAL LLC, ET AL.
Neutral
Accesswire
about one month ago
DENVER, CO / ACCESSWIRE / November 22, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced it ranked 380th on the Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, now...
Neutral
Seeking Alpha
about 2 months ago
Aytu BioPharma, Inc. (NASDAQ:AYTU ) Q1 2025 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Robert Blum - IR, Lytham Partners Josh Disbrow - Chief Executive Officer Mark Oki - Outgoing Chief Financial Officer Ryan Selhorn - Chief Financial Officer Conference Call Participants Naz Rahman - Maxim Group Operator Greetings. Welcome to the Aytu BioPharma Fiscal 2025 Q1 Ear...
More Aytu BioScience Inc News

Company Profile

Aytu BioScience, Inc. is a specialty pharmaceutical company, which focuses on identifying, acquiring, and commercializing novel products. Its products include Natesto, Tuzistram, ZolpiMist and MiOXSYS. The company was founded on August 9, 2002 and is headquartered in Englewood, CO.

Head office United States
CEO John Donofrio
Founded 2002
Website www.aytubio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today